Jun. 11 at 8:47 PM
BTIG said Stryker's Mako robotic system has emerged as the leading platform for ambulatory surgery centers (ASCs), as robotic-assisted procedures increasingly shift from being optional to becoming a competitive necessity. Following Becker's Healthcare conference in Chicago, analyst Ryan Zimmerman reiterated a Buy rating on Stryker with a
$379 price target, highlighting Mako's multispecialty capabilities as a key advantage.
BTIG also maintained Buy ratings on Medtronic, Boston Scientific, and Solventum, while keeping Neutral ratings on Zimmer Biomet and Globus Medical. According to conference participants, flexible contracting models offered by companies such as Stryker have lowered financial barriers for ASCs, while growing demand from both younger surgeons and patients has accelerated robotic adoption.
$SYK $MDT $BSX $ZBH $GMED